Kura Oncology Inc - Asset Resilience Ratio
Kura Oncology Inc (KURA) has an Asset Resilience Ratio of 76.35% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kura Oncology Inc (KURA) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Kura Oncology Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Kura Oncology Inc.
Liquid Assets Composition Over Time
This chart breaks down Kura Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Kura Oncology Inc debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $448.78 Million | 76.35% |
| Total Liquid Assets | $448.78 Million | 76.35% |
Asset Resilience Insights
- Very High Liquidity: Kura Oncology Inc maintains exceptional liquid asset reserves at 76.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kura Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Kura Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Kura Oncology Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Kura Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.17% | $518.14 Million | $738.36 Million | +4.01pp |
| 2024-12-31 | 66.16% | $502.93 Million | $760.16 Million | -19.96pp |
| 2023-12-31 | 86.12% | $386.64 Million | $448.94 Million | +1.49pp |
| 2022-12-31 | 84.63% | $386.18 Million | $456.31 Million | +4.62pp |
| 2021-12-31 | 80.01% | $427.29 Million | $534.05 Million | +32.45pp |
| 2020-12-31 | 47.56% | $307.83 Million | $647.21 Million | -39.54pp |
| 2019-12-31 | 87.10% | $210.76 Million | $241.97 Million | -2.20pp |
| 2018-12-31 | 89.30% | $162.87 Million | $182.38 Million | +4.05pp |
| 2017-12-31 | 85.25% | $81.71 Million | $95.85 Million | +2.09pp |
| 2016-12-31 | 83.16% | $58.06 Million | $69.82 Million | +2.59pp |
| 2015-12-31 | 80.57% | $70.30 Million | $87.26 Million | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more